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Increased Valvular Fluorodeoxyglucose Uptake in Aortic Stenosis
Objectives Because fluorodeoxyglucose positron emission tomography (FDG-PET) imaging provides a noninvasive index
of inflammation, we sought to assess whether FDG uptake in the aortic valve (AV) is increased in aortic
stenosis (AS).
Background AS is associated with valvular inflammation.
Methods FDG-PET/computed tomography data were retrospectively evaluated in 84 patients (age 73  9 years, 45% fe-
male), 42 patients with AS, and 42 age-matched controls. FDG uptake was determined within the AV while
blinded to AS severity. Target-to-background ratio (TBR) was calculated as valvular/blood activity. Stenosis sever-
ity was established on echocardiography, and presence of AV calcification was independently assessed on com-
puted tomography.
Results The aortic valve PET signal (TBR) was increased in AS compared with controls (median 1.53 [interquartile range
(IQR): 1.42 to 1.76] vs. 1.34 [IQR: 1.20 to 1.55]; p  0.001). Further, compared with controls, TBR was in-
creased in mild (median 1.50 [IQR: 1.36 to 1.75]; p  0.01) and moderate (median 1.70 [IQR: 1.52 to 1.94];
p  0.001), but not in severe AS (median 1.49 [IQR: 1.40 to 1.54]; p  0.08). When subjects were categorized
according to AV calcification, valvular FDG uptake was increased in mildly (median 1.50 [IQR: 1.36 to 1.79]; p 
0.01) and moderately (median 1.67 [IQR: 1.50 to 1.85]; p  0.001), but not severely calcified valves (median
1.51 [IQR: 1.38 to 1.54]; p  0.15), compared with noncalcified valves (median 1.35 [IQR: 1.20 to 1.52]).
Conclusions This study supports the hypothesis that AS is an inflammatory condition and suggests that inflammation may be
reduced in late-stage disease. This may have important implications in the design of studies assessing the effect
of therapeutic agents in modifying progression of AS. (J Am Coll Cardiol 2011;57:2507–15) © 2011 by the























oOnce considered to represent the result of years of mechanical
stress on an otherwise normal valve, the evolving concept is
that calcific aortic stenosis (AS) results from active proliferative
and inflammatory changes, with lipid accumulation, up-
regulation of angiotensin-converting enzyme activity, and in-
filtration of macrophages and T-lymphocytes ultimately lead-
ing to calcium deposition in a manner analogous to vascular
calcification (1–4). Progressive calcification further leads to
immobilization of the cusps.
However, there are no direct clinical data to either
support or refute a link between local inflammation within
aortic valves (AVs) and progression of AS. A primary reason
for the absence of such studies is that there has not been a
reliable method to noninvasively measure AV inflammation.
Numerous positron emission tomography (PET) studies
demonstrate that fluorodeoxyglucose (FDG) uptake is in-
creased in inflamed tissues such as tumors and infectious
foci (5–7). Several groups have demonstrated that FDG-
PET imaging provides a measure of inflammation, both
in animal models (8,9) and humans (10 –13). Further-
more, measurement of metabolic activity within the
aortic root (including the AV annulus) and coronary tree
is feasible (14).
Accordingly, we sought to test the hypothesis that the AV
PET signal is increased in stenotic AVs compared with
matched controls. Second, we sought to test the hypothesis
that the inflammatory signal varies across groups of patients
according to severity of AS and severity of valve calcification. pMethods
Subjects. In a retrospective observational study, 84 patients
(age 73  9 years, 47% female; 42 with AS and 42
ge-matched control patients without AS) were identified
rom a database of subjects who underwent PET/computed
omography (CT) imaging between 2005 and 2010, primar-
ly for evaluation of neoplastic process. The patients with
S were identified by cross-referencing our institution’s
linical PET and echocardiography (echo) patient data-
ases, thereby identifying all patients with: 1) echo-
onfirmed diagnosis of AS; and 2) PET scanning within 6
onths of the echo examination (Fig. 1). To ensure that the
Vs were representative of degenerative AS, exclusion
riteria included the following: evidence of rheumatic dis-
ase, endocarditis, Marfan’s syndrome, known significant
ortic regurgitation, or presence of other significant valvular
isease. The control group of 42 subjects without AS was
onstructed by 1:1 age matching to subjects in the AS
roup. Accordingly, we ultimately analyzed the image da-
asets for analysis of the first 42 control subjects from the
riginal PET database who met the following criteria:
) age within 6 years of a subject with AS; 2) no known AS
y echo or clinical exam findings concerning for AS; 3) no
ther exclusion criteria.
etermination of AS severity. Severity of AV stenosis
as established on echo, using standard American College
f Cardiology/American Heart Association criteria (15). AS
atients were accordingly classified in 3 groups: those with
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stenosis severity was done while investigators were blinded
to the PET and CT data.
FDG-PET/CT imaging and measurement of AV
activity. FDG-PET imaging was performed on a PET-CT
scanner (Biograph 16, Siemens, Forcheim, Germany, or sim-
ilar system). Briefly, FDG was administered (10 to 20 mCi)
intravenously after an overnight fast, and PET images were
acquired 1 to 3 h later in 3-dimensional mode. Patients were
imaged in the supine position, and images were obtained over
15 to 20 min. A low-dose, nongated, noncontrast-enhanced
CT (120 keV, 50 mAs) preceded the PET scan. Attenuation
correction was done for all PET datasets.
FDG uptake was measured within the central portion of
the AV apparatus. To accomplish this, the acquired PET
and CT datasets were manually coregistered using a multi-
modality fusion workstation (Leonardo TrueD, Siemens) by
an investigator who was blinded to the patients’ status and
to the CT and echo evaluations. To register the images, we
prioritized the registration of the ascending aorta given that
it was discernible on both PET and CT image sets. Once
co-registered, maximum standardized uptake value (SUV)
of FDG was measured within the central portion of the AV.
The CT images were used to guide placement of 5-mm3
volume of interest (VOI) within the center of the AV
apparatus, with the goal of minimizing the inclusion of
signal (spillover) derived from the left ventricular myocar-
dium, as well as possible atherosclerotic uptake in the arterial
wall (Fig. 2). To obtain a background value for FDG uptake,
blood SUV was determined by placement of 3 1-cm3 VOIs
Figure 1 Study Flow Chart
AS  aortic stenosis; CT  computed tomography; echo  echocardiography; MGwithin the right atrial activity, in
locations devoid of significant
spillover activity. The AV com-
missural target-to-background
ratio (TBR) was calculated by
dividing the AV SUV by atrial
blood SUV.
Reproducibility of measurement
of AV FDG uptake. The inter-
reader and intrareader variability
was evaluated in repeated mea-
sures of 66 patients. Inter-reader
variability was assessed by com-
paring the AV measurements de-
rived by 2 independent readers.
The intra-reader variability was
assessed by repeat measurement
of the primary reader (A.T.) ap-
proximately 6 months after the
initial reads were performed. The
blinded interobserver and intra-
observer reliability analysis for the FDG uptake reading
(TBR) in 66 cases revealed intraclass correlation coefficients
of 0.97 (95% confidence interval [CI]: 0.96 to 0.98) and
0.55 (95% CI: 0.27 to 0.73), respectively. Bland-Altman
curves are provided as supplemental data.
FDG-PET/CT imaging andmeasurement of aorta activity.
We also measured FDG signal in the aortic wall in order to
enable a comparison between vascular and valvular FDG
uptake in the same patients. This was done by placing
Abbreviations
and Acronyms
AS  aortic stenosis
AV  aortic valve
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VOI  volume of interest
assachusetts General Hospital; PET  positron emission tomography.H  M
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images at 5-mm intervals, starting 2.5 cm above the AV (to
avoid spillover from the valve) and extending to the aortic
arch. The TBR of the aorta was calculated by dividing the
aorta SUV by atrial blood SUV. All aorta FDG uptake
measurements were done by an investigator who was
blinded to the AV FDG uptake data.
Assessment of AV calcification. The extent and severity of
calcium deposition within the AV was assessed on trans-
verse reconstructions of the chest CT as reported by
Willmann et al. (16). Briefly, the AV calcifications were
graded qualitatively as grade 1 (no calcification), grade 2
(mildly calcified; small isolated spots), grade 3 (moderately
calcified; multiple larger spots); or grade 4 (heavily calcified;
extensive calcification of all cusps) (Fig. 3). In a subset of 14
patients, low-dose CT images were unavailable and were
replaced with chest CT imaging data obtained on a dedi-
cated CT scanner using clinical protocols.
Evaluation of AV disease progression. We sought to test
the hypothesis that an increased initial AV PET signal is
associated with subsequent progression of AV stenosis. This
analysis was done in the subset of patients who had a repeat
echo examination between 1 and 2 years after the initial
echo and who did not undergo AV replacement during the
observation period. Serial echo data meeting these criteria
were available for 19 subjects. Thereafter, progression of AS
was adjudicated by an investigator (Q.T.) who was blinded
to all other clinical and PET data. Progression was defined
as any increase in severity class based on any 1 of the 3
components (valve area, peak velocity, and mean gradient)
Figure 2 Placement of Region of Interest
Within the Aortic Valve Apparatus
Coregistered fluorodeoxyglucose positron emission tomography/computed
tomography image demonstrate 5-mm3 volume of interest (VOI) focused on the
center of the aortic valve apparatus (arrow).using standard American College of Cardiology/AmericanHeart Association criteria (15). Patients with critical AS on
the initial echo were excluded because they could not
experience an increase in disease progression based on this
classification scheme. Accordingly, 15 patients with AS
were ultimately included in this analysis. A high baseline
AV TBR was defined as a TBR value that is above the
median value for all patients with AS. Subsequently, we
compared progression (vs. no progression) of AV disease in
patients with high (vs. low) AV TBR.
Statistical methods. Descriptive analysis was reported as
mean  SD or median (interquartile range [IQR]) for
continuous variables and frequency with percentages for
nominal variables, as appropriate. For analysis of the base-
line characteristics of the age-matched AS and control
groups, we used paired t tests for normal continuous
variables, related samples Wilcoxon rank sum tests for
non-normal continuous variables, and related samples Mc-
Nemar test for binary variables. To evaluate differences
between subgroups in FDG uptake (a non-normally distrib-
uted continuous variable), the Mann-Whitney U (Wil-
coxon) rank sum test was used. A linear regression analysis
was used to assess the strength of the association between
the FDG signal and the presence of AS while controlling
for potential confounding variables. Intraclass correlation
coefficient was calculated to determine interobserver reli-
ability using the TBR max obtained by the readers during
the reliability analysis. Additionally, a Fisher exact test was
used in the subset of AS patients to test the relationship
between 2 unrelated binary variables: AV signal (low vs.
high) versus progression of AS (present or absent). All
Figure 3 Grading of Aortic Valve Calcification
Diagrams of different grades of aortic valve calcification: grade 1, no calcifica-
tion; grade 2, mildly calcified (small isolated spots); grade 3, moderately calci-
fied (multiple larger spots); grade 4, heavily calcified (extensive calcification of
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Chicago, Illinois). A value of p  0.05 was considered
significant. A Bonferroni correction was used as appropriate
for multiple comparisons.
Results
Demographic information is summarized in Table 1. The
disease severity distribution across the AS group was as
follows: mild AS (n  18), moderate AS (n  16), and
evere AS (n  8) (Table 2).
The AV PET signal (TBR) was increased in patients
ith AS compared with matched controls: median 1.53
IQR: 1.42 to 1.76) versus 1.34 (IQR: 1.20 to 1.55); p 
.001 (Fig. 4A). The difference in TBR between patients
ith and without AS remained significant after correcting
or age, sex, presence of hyperlipidemia, clinical coronary
rtery disease, and previous statin treatment, resulting in a
ean increase in TBR of 0.27 [IQR: 0.14 to 0.40] in AS
ersus controls (mean, 95% CI, p  0.001). Likewise, the
ifference in TBR between patients with and without AS
emained significant after correcting for tracer circulation
ime, resulting in a mean increase in TBR of 0.20 (IQR:
.04 to 0.36) in AS versus controls (p  0.01).
The uncorrected measure of valvular FDG uptake (SUV)
as not different between the AS and control groups





(n  42) p Value*
Female 18 (43%) 20 (48%) 0.73
Age, yrs 73.6 9.0 73.3 9.0 0.46
Coronary artery disease 20 (48%) 12 (29%) 0.1
Hypertension 26 (62%) 20 (48%) 0.33
Hypercholesterolemia 25 (60%) 21 (50%) 0.54
Diabetes mellitus 10 (24%) 5 (12%) 0.06
Statin use 23 (52%) 24 (57%) 0.85
Tracer circulation time, min 70 20 62 14 0.06
Values are n (%) or mean SD. *p values for statistical difference between groups were calculated
y related sample Wilcoxon signed rank test (continuous values) and related samples McNemar
est (binary values).
AS  aortic stenosis.
Aortic Stenosis Group CharacteristicsTable 2 Aortic Stenosis Group Characteristi
Characteristic Mild
Aortic-jet velocity, m/s 2.




2, mild (isolated small spots) 13
3, moderate (multiple larger spots) 3
4, severe (heavy calcification of all cusps)Values are mean  SD or n (%).
AS  aortic stenosis; AV  aortic valve.median 1.93 [IQR: 1.66 to 2.5] vs. 1.88 [IQR: 1.55 to
.22]; p  0.24). Similarly, the venous blood (background)
UV was not different between the 2 groups (median 1.24
IQR: 1.04 to 1.70] vs. 1.39 [IQR: 1.10 to 2.04]; p 0.44).
owever, the difference in valvular SUV between patients
ith and without AS was significant after correcting for
ackground SUV, resulting in a mean increase in SUV of
.29 [IQR: 0.15 to 0.43] in AS versus controls (p  0.001).
Moreover, the ratio of SUV in the AV to that within the
wall of the ascending aorta within the same patients
(valve-to-wall uptake ratio) was significantly higher in AS
compared with controls (median 0.99 [IQR: 0.91 to 1.14]
vs. 0.90 [IQR: 0.81 to 0.98]; p  0.001).
There was a significant difference in TBR across sub-
groups stratified according to AS severity (p  0.0001).
Compared with FDG uptake in patients without AS
AS Severity Subgroups
8) Moderate (n 16) Severe (n  8)
3 3.5 0.5 4.0 0.6
8 27.7 9.5 55.8 19.7
1.01 0.28 0.68 0.22
1 (6%) 0
) 3 (19%) 0
9 (56%) 3 (38%)
3 (19%) 5 (62%)
Figure 4 FDG Uptake Versus Aortic Stenosis
(A) Aortic FDG-PET signal in AS group versus no-AS group. (B) Aortic FDG-PET
signal across subgroups according AS severity. Although target-to-background
ratio (TBR) was increased in mild and moderate AS, it was not increased in
severe AS compared with controls. *p  0.01, mild AS versus control; **p 
0.001, moderate AS versus controls; #p  0.01, moderate AS versus severe
AS (p  NS for severe AS vs. controls). FDG  fluorodeoxyglucose; other
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mild (median 1.57 [IQR: 1.44 to 1.75]; p  0.01) and
moderate (median 1.76 [IQR: 1.52 to 1.95]; p  0.001),
ut not in severe AS (median 1.49 [IQR: 1.38 to 1.54];
 0.08) (Fig. 4B). Representative images are shown in
igure 5.
Similar trends were observed when subjects were
rouped according to AV calcification (independent of
S severity). The PET signal was increased in calcified
Vs compared with noncalcified controls: (median 1.54
IQR: 1.44 to 1.77] vs. 1.35 [IQR: 1.20 to 1.52]; p 
.001) (Fig. 6A). Moreover, compared with the FDG
ptake in noncalcified AVs (median 1.35 [IQR: 1.20 to
.52]), TBR was increased in mildly (median 1.51 [IQR:
.36 to 1.80]; p  0.01) and moderately (median 1.67 [IQR:
.50 to 1.85]; p  0.001), but not severely calcified valves
median 1.51 [IQR: 1.38 to 1.54]; p  0.13) (Fig. 6B). As
nticipated, there was a significant correlation between valvular
alcification grade and AS severity (r  0.90, p  0.001).
Furthermore, we analyzed the relationship between the
nitial FDG uptake in the AV and the subsequent progres-
ion of AV stenosis. Patients with high AV TBR ( median
BR value of 1.54) had a higher likelihood of stenosis
rogression on repeat echo, obtained 1 to 2 years after the
ndex echo. Specifically, 5 of 6 patients (83%) with high
nitial AV TBR experienced subsequent progression of AS,
ompared with 2 of 9 patients (22%) with low TBR (p 
.04 by Fisher exact test).
iscussion
his study demonstrates for the first time that FDG uptake
s increased within AVs of patients with AS. We found that
DG uptake is increased in mild and moderate AS, but not
Figure 5 Example PET and CT Images
(A) CT images of AV with different degree of AS and valve calcification. (B) Coregi
and moderate AS (arrows) compared with lower uptake in severe AS and normal An the more severe stage of the disease. In parallel with these
bservations, we found a similar association between the
DG signal and the degree of AV calcification. Further-
ore, in a subset of patients, we found that the valvular
BR is increased in patients who subsequently experience
rogression of AS. These observations support the hypoth-
FDG-PET/CT images demonstrate increased FDG uptake in AV of mild
 aortic valve; FDG  fluorodeoxyglucose; other abbreviations as in Figure 1.
Figure 6 FDG Uptake Versus Aortic Calcification
(A) Aortic FDG-PET signal in calcified versus noncalcified AV. (B) Aortic FDG-PET
signal across subgroups according degree of calcification. Although target-to-
background ratio (TBR) was increased in mildly and moderately calcified AV, it
was not increased in severely calcified valves. *p  0.01, mild calcification
versus no calcification; **p  0.001, moderate calcification versus no calcifi-
cation; #p  0.01, moderate calcification versus severe calcification (p  NS
for severe calcification vs. no calcification); #p  0.01, moderate calcification
versus severe calcification (p  NS for severe calcification vs. no calcification).
Abbreviations as in Figure 5.stered
V. AV
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a novel method to evaluate the pathobiological processes
involved in AS.
FDG-PET imaging as a measure of inflammation. We
observed increased glycolytic metabolic activity within the
AV in AS and postulate that this in turn represents AV
inflammatory cell (specifically macrophage) activity. Indeed,
other cells within the valve, including fibroblasts, would not
be expected to generate the increased signal (13). Further,
the median signal measured in the mild to moderate AS
group in this study is consistent with the signal that would
be found within large atherosclerotic plaques with at least
moderate macrophage staining (13). Although these points
suggest that valvular FDG uptake is a function of valvular
inflammation, this observation will need more direct
validation.
Inflammation and calcification in AS. Our observation,
that inflammation is increased in mild to moderate AS but
reduced in late-stage disease, is reminiscent of what has
been observed in atherosclerotic disease. In an animal model
of atherosclerosis, Aikawa et al. (17) recently reported a
negative interrelationship between inflammation and calci-
fication. Likewise, several studies in humans have noted that
macrophage density is higher in early plaques with high
content of lipid and hemorrhage and reduced in advanced
plaques dominated by calcification and fibrous tissue (18–20).
Rudd et al. (21) recently reported that the FDG-PET signal
is reduced in atherosclerotic lesions that are calcified,
observing that plaque inflammation and calcification rarely
overlap.
Similar trends have been noted for inflammation in AS.
Animal models of AS demonstrate that macrophages accu-
mulate in the early AV lesions (22). In humans, Otto et al.
(1) observed that the early lesion of “degenerative” AS is an
active inflammatory process. Others have shown that al-
though earlier AV lesions are characterized by infiltration of
inflammatory cells, late lesions were characterized by for-
mation of calcific plaque and a relative reduction in inflam-
mation (23,24). Similarly, in mild AS, microscopic “spotty”
calcifications are seen co-localizing to areas of lipoprotein
accumulation and inflammatory cell infiltration, whereas in
later stage disease, active bone formation is seen (4,25).
Consistent with previously described histological observa-
tions, our study suggests that inflammation may be reduced
in late-stage disease.
Inflammatory biomarkers in AS. If inflammation is the
fundamental process of early AV disease, with calcification
predominating in the later stages, one might anticipate that
systemic biomarkers of inflammation, such as C-reactive
protein (CRP), might prove useful for predicting disease
progression. However, Novaro et al. (26) showed that
progression of AS is not well predicted by CRP values. A
concern that has been since raised about that observation is
that the inflammatory focus within the AV might not be
large enough to affect a systemic biomarker such as CRP(27). Thus it may be useful to identify a local biomarker of
AV inflammation, rather than a systemic one, to predict
patients likely to develop aortic sclerosis and those likely to
progress to AS (27). Accordingly, the PET imaging method
used in the current study has potential to serve as a local
biomarker to study changes in inflammation and metabo-
lism relative to the valvular disease process.
Targeting inflammation in AS. Given the broad overlap
in the pathophysiologies of atherosclerosis and AS, statin
therapy has been proposed as a way to slow the rate of
progression of AS. Indeed, several small retrospective stud-
ies have suggested a benefit (28–31). However, more
recently published larger prospective studies of statin use in
AS failed to demonstrate a beneficial effect on stenosis
progression (32–34). It is not clear why statins failed to
modify progression of this inflammatory disease. It is
conceivable that inflammation in AS is less responsive to
statins compared with atherosclerotic inflammation and that
compounds acting as direct anti-inflammatory agents may
be more effective. Future studies evaluating the effect of
anti-inflammatory therapies on AS progression might ben-
efit from measurement of aortic valvular inflammation,
possibly using the methods described in this paper, to
determine eligibility and, perhaps, as an additional measure-
ment of efficacy.
Further, the negative statin trials do not refute the
potential importance of inflammation to the underlying AS
pathobiology. Our study supports the theory that AS is an
active inflammatory condition with high metabolic activity
and further confirms that the early and mid stages of the
disease are the metabolically active stages, which might
represent optimal targets for future treatment trials.
Furthermore, we observed that patients with high aortic
valvular FDG uptake are more likely to experience progres-
sion of AV stenosis than patients with a low AV signal.
Although these findings are highly preliminary and are
derived from a limited dataset, they do provide initial
insight into the potential role for biological imaging to
provide prognostic information regarding patients with
valvular disease. This encouraging observation will require
confirmation in a larger prospective trial.
Study limitations. Several methodological limitations
should be noted. First, the PET-CT methodology used in
this study was not optimized for measurement of inflam-
mation. Several studies (10,13) suggest that an optimal time
for inflammation imaging is 180 min after FDG injection
(whereas in clinical practice, 45 to 75 min after injection is
the norm). Additionally, it would have been preferable to
use electrocardiography gating of the PET imaging. How-
ever, despite these technical limitations, we observed a
substantial difference across the AS groups. It is possible
that the between-group differences would have been greater
had the imaging parameters been optimized.
Second, the measurement of valvular FDG uptake is a
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images and to identify the center of the AV apparatus.
Although such image registration and evaluation currently
requires manual input and judgment, it is expected that
automatic registration methods could be optimized for
co-registration of the aortic root should PET imaging of the
AV become more commonplace.
Although we observed that the co-registration and mea-
surement process was reproducible within ROI focused in
5-mm3 sample volume of the AV commissure, we acknowl-
dge that the data sampled for PET measurements extend
eyond the drawn VOI (owing to the resolution of PET).
owever, we had chosen the small VOI to constrain
ocalization of the ROI to the center of the AV. This rather
mall, centrally placed VOI thereby served to limit inclusion
f spillover activity from the myocardium and aortic wall
whose inflammatory signal may reflect atherosclerosis
ather than valvular inflammation). The measurement of
DG uptake in the small ROI within the AV is limited by
he small size of the ROI as well as by motion of the cardiac
alve. This likely leads to underestimation of the true valve
ctivity. Furthermore, prospective trials are needed to eval-
ate the true reproducibility of the AV signal using this
echnique, because only reproducibility of the image analysis
s provided here. Once such reproducibility data are avail-
ble, interventional studies can be designed to evaluate the
ffect of treatment on AV disease progression.
It should also be noted that there is substantial overlap in
alues for valvular TBR between patients with and without
S. Much of the overlapping values between patients with
S (vs. controls) are derived from patients with mild and
evere AS (less overlap is seen in the patients with moderate
S). It is possible that the overlap is caused by inherent
imitations in the accuracy of the measurement. It is also
lausible that the control patients without AS who have
igher valvular TBR values will eventually develop AS, a
ypothesis that should be explored prospectively.
uture directions. The pursuit of therapies aimed at mod-
fying the progression of AV stenosis is a challenging but
otentially worthwhile endeavor. Thus far, the approach of
sing statins to modify disease progression using echocar-
iographic endpoints has been disappointing. The further
evelopment of molecular imaging tools to assess therapeu-
ic efficacy at the tissue level of the AV may provide
mportant new opportunities to develop new treatment
trategies. An important next step in evaluating PET-CT
maging of the AV is to prospectively test whether the
DG-PET signal is associated with progression of AS. If
uch a study demonstrates that the PET signal predicts
rogression, then the imaging tool might be used to identify
nti-inflammatory agents that modify valvular inflamma-
ion. Indeed, the ability to noninvasively assess AV inflam-
ation at molecular level would likely serve as a powerful
timulus for intensification of efforts to develop such ther-
pies aimed at AV stenosis.onclusions
his preliminary study demonstrates that FDG uptake is
ncreased in AS, thereby supporting the hypothesis that
nflammation is present in AS. Further, the FDG signal is
ncreased in mild and moderate AS, but not in severe AS, a
nding that suggests that inflammation may play an impor-
ant role in early but not late disease. Accordingly, FDG-
ET/CT imaging potentially represents a novel molecular
maging method for characterizing the biological activity
ithin the AV. This technique, once further validated, may
rovide new opportunities for risk stratification of patients
nd for identification of treatments to modify the progres-
ion of AS.
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